PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis

Company Overview

PHAXIAM Therapeutics is a clinical-stage biopharmaceutical company focused on developing bacteriophage-based therapies for serious bacterial infections, particularly infections caused by antimicrobial-resistant bacteria. Bacteriophages are viruses that selectively target and destroy specific bacterial strains, offering a potential alternative or complement to conventional antibiotics.

The company’s development programs are aimed at addressing difficult-to-treat infections involving pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa. Its approach involves identifying and developing phages with activity against targeted bacteria and evaluating them in clinical and compassionate-use settings. The company’s programs remain investigational and are subject to clinical and regulatory review.

PHAXIAM was formerly known as ERYTECH Pharma, a company that developed red-blood-cell-based therapeutics, before adopting its current name following the combination with Pherecydes Pharma. The company is headquartered in France and conducts development activities in Europe and the United States. Its shares trade on Nasdaq under the symbol PHXM.

Key Stats

• Today's Range: $3.10 to $3.10
• 50-Day Range: $3.10 to $3.10
• 52-Week Range: $2.50 to $13.00
• Volume: N/A
• Average Volume: 2,472 shs
• Market Capitalization: $10.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PHXM
• CIK: 1624422
• Web: phaxiam.com
• Phone: 33478744438
• Fax: 33-4-78-75-56-29
• Employees: 49
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 1.78
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.98 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 3,412,000
• Free Float: 3,346,000
• Market Cap: $10.58 million
• Optionable: No Data
• Beta: 2.35